These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

550 related items for PubMed ID: 18076218

  • 1. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects.
    Stangier J, Stähle H, Rathgen K, Fuhr R.
    Clin Pharmacokinet; 2008; 47(1):47-59. PubMed ID: 18076218
    [Abstract] [Full Text] [Related]

  • 2. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
    Stangier J, Rathgen K, Stähle H, Gansser D, Roth W.
    Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement.
    Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stähle H, Rathgen K, Svärd R.
    J Clin Pharmacol; 2005 May; 45(5):555-63. PubMed ID: 15831779
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate.
    Stangier J.
    Clin Pharmacokinet; 2008 May; 47(5):285-95. PubMed ID: 18399711
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin.
    Stangier J, Stähle H, Rathgen K, Roth W, Reseski K, Körnicke T.
    J Clin Pharmacol; 2012 Feb; 52(2):243-50. PubMed ID: 21868715
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.
    Eriksson BI, Dahl OE, Ahnfelt L, Kälebo P, Stangier J, Nehmiz G, Hermansson K, Kohlbrenner V.
    J Thromb Haemost; 2004 Sep; 2(9):1573-80. PubMed ID: 15333033
    [Abstract] [Full Text] [Related]

  • 13. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.
    Stangier J, Clemens A.
    Clin Appl Thromb Hemost; 2009 Sep; 15 Suppl 1():9S-16S. PubMed ID: 19696042
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Pharmacokinetics and pharmacodynamics of the new oral anticoagulants dabigatran and rivaroxaban].
    Ordovás Baines JP, Climent Grana E, Jover Botella A, Valero García I.
    Farm Hosp; 2009 Sep; 33(3):125-33. PubMed ID: 19712596
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability.
    Halton JML, Albisetti M, Biss B, Bomgaars L, Brueckmann M, Gropper S, Harper R, Huang F, Luciani M, Maas H, Tartakovsky I, Mitchell LG.
    J Thromb Haemost; 2017 Nov; 15(11):2147-2157. PubMed ID: 28921890
    [Abstract] [Full Text] [Related]

  • 18. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate.
    Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N.
    Thromb Haemost; 2007 Jul; 98(1):155-62. PubMed ID: 17598008
    [Abstract] [Full Text] [Related]

  • 19. Oral bioavailability of dabigatran etexilate (Pradaxa(®) ) after co-medication with verapamil in healthy subjects.
    Härtter S, Sennewald R, Nehmiz G, Reilly P.
    Br J Clin Pharmacol; 2013 Apr; 75(4):1053-62. PubMed ID: 22946890
    [Abstract] [Full Text] [Related]

  • 20. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial.
    Liesenfeld KH, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD, Yusuf S, Wallentin L, Haertter S, Staab A.
    J Thromb Haemost; 2011 Nov; 9(11):2168-75. PubMed ID: 21972820
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.